首页|基于生信分析评价前列腺癌TP53表达和第10号染色体上缺失与张力蛋白同源的磷酸酯酶基因相关性

基于生信分析评价前列腺癌TP53表达和第10号染色体上缺失与张力蛋白同源的磷酸酯酶基因相关性

扫码查看
目的 基于生信分析评价前列腺癌(PCa)中TP53及第10号染色体上缺失与张力蛋白同源的磷酸酯酶基因(PTEN)的表达水平及相关性。方法 利用生物信息学方法,挖掘公开数据库,分析TP53基因在前列腺癌中的表达并分析其可能的调控机制。收集徐州医科大学附属医院泌尿科2022年3月至2022年8月间诊治的PCa 79例,复阅病理切片并整理相关临床资料,采用免疫组织化学SP染色法检测79例PCa中PTEN及TP53的蛋白表达水平。分类资料的组间比较采用卡方检验和Mann-Whitney U检验,应用Pearson相关分析前列腺癌患者中PTEN和TP53的相关性。结果 通过TCGA数据库分析,TP53在前列腺癌组织中的表达水平明显高于正常组织(501个比52个,Z=8 874。5,P<0。05);TP53表达水平(低表达250例比高表达251例)与前列腺癌患者临床病理参数关系表明,TP53与患者年龄(x2=6。079,P>0。05)、T分期(x2=0。338,P>0。05)、N分期(x2=0。176,P>0。05)、PSA 水平(x2=0。016,P>0。05)和 Gleason 评分(x2=3。999,P>0。05)在内的临床特征之间均无统计学意义;建立前列腺癌总体生存期(OS)预测列线图,分析得出TP53不能作为OS的独立预后因素,PSA值与Gleason评分在前列腺有预后作用;免疫组织化学染色PTEN蛋白阳性(完整)者占73%,阴性(缺失)者占27%;TP53蛋白染色呈野生型突变模式者占81%,突变型表达模式者占19%。Pearson统计学分析,PTEN缺失与TP53突变型显著相关性(r=0。653,P<0。05)。结论 TP53联合PTEN对前列腺癌的进展有一定预测作用,且为临床前列腺癌治疗提供参考。
Expression of TP53 in prostate cancer and its correlation with phosphatase and tensin homologue deleted on chromosome ten were evaluated based on bioinformatics analysis
Objective To evaluate the expression levels and correlation of TP53 and phosphatase and tensin homologue deleted on chromosome ten(PTEN)in prostate cancer(PCa)based on bioinformatics analysis.Methods The expression of TP53 gene in prostate cancer and its possible regulatory mechanism were analyzed by mining public databases using bioinformatics methods.A total of 79 cases of PCa diag-nosed and treated in the Department of Urology,the Affiliated Hospital of Xuzhou Medical University from March to August 2022 were collected.The pathological sections were reviewed and the relevant clinical data were sorted out.The protein expression levels of PTEN and TP53 in 79 cases of PCa were detected by im-munohistochemical SP staining,and Pearson correlation analysis was used to analyze their correlation.Chi-square test and Mann-Whitney U test were used for comparison of categorical data between groups.Pearson correlation analysis was used to analyze the correlation between PTEN and TP53 in prostate cancer patients.Results Through TCGA data analysis TP53 expression level was significantly higher in patients with prostate cancer(501 cases vs.52 cases,Z=8 874.5,P<0.05)in normal people;The relationship between TP53 expression level and clinicopathological parameters of prostate cancer patients showed that(250 cases of lower expression vs.251 cases of high expression):TP53 was not significantly associated with clinical characteristics including age(x2=6.079,P>0.05),T stage(x2=0.338,P>0.05),N stage(x2=0.176,P>0.05),PSA level(x2=0.016,P>0.05)and Gleason score(x2=3.999,P>0.05).The nomogram for predicting the overall survival(OS)of PCa was established.The analysis showed that TP53 could not be used as an independent prognostic factor for OS,and PSA value and Gleason score had prognostic effects in PCa.Immunohistochemical staining showed that the positive rate of PTEN protein(intact)was 73%.TP53 protein staining showed wild type mutation pattern in 81%cases,and mutant ex-pression pattern in 19%cases.Pearson analysis showed that PTEN loss had a higher correlation with p53 mutation(r=0.653,P<0.05).Conclusion TP53 combined with PTEN has a certain predictive effect on the progression of PCa,and has important value in the clinical treatment of prostate cancer.

Prostatic carcinomaPhosphatase geneTP53Immunohistochemistry

刘参军、彭阳、张洁琳、徐琪卿、杨春华

展开 >

永城市中心医院泌尿外科,永城 476600

徐州医科大学第一临床学院,徐州 221002

前列腺癌 磷酸酯酶基因 TP53 免疫组织化学

国家卫健委资助项目

GWJJ2020100303

2024

中华实验外科杂志
中华医学会

中华实验外科杂志

CSTPCD
影响因子:0.759
ISSN:1001-9030
年,卷(期):2024.41(7)
  • 7